Table 3 Hazard ratios of disease-free survival and predictive capacity according to the WHO 2017 classification versus alternative grouping.
From: Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations
Staging | No of patients (n) | No of recur (n) | DFS 5-year (%) | DFS 10-year (%) | DFS 15-year (%) | Hazard ratio (95% CI) | P-value | PVE | C-index |
|---|---|---|---|---|---|---|---|---|---|
WHO-2017 | 14.9 | 0.794 | |||||||
MI-FTC | 39 | 3 | 100 | 95.2 | 90.2 | Reference | |||
EA-FTC | 24 | 3 | 91.7 | 85.6 | 85.6 | 1.56 (0.31–7.73) | 0.587 | ||
WI-FTC | 14 | 8 | 42.9 | 42.9 | 42.9 | 9.06 (2.40–34.22) | 0.001 | ||
Alternative group | 27.1 | 0.846 | |||||||
Group 1 | 58 | 4 | 100 | 94.5 | 91.7 | Reference | |||
Group 2 | 9 | 3 | 66.7 | 66.7 | 66.7 | 4.92 (1.10–22.04) | 0.037 | ||
Group 3 | 10 | 7 | 0.0 | 0.0 | 0.0 | 38.80 (8.35–180.27) | <0.001 |
